Epigenetics of melanoma: Implications for immune-based therapies

Immunotherapy

Volumn 5, Issue 10, 2013, Pages 1103-1116

  Fratta, Elisabetta ^a   Sigalotti, Luca ^a   Covre, Alessia ^b   Parisi, Giulia ^b   Coral, Sandra ^b   Maio, Michele ^b  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

5 aza 2 deoxycytidine; DNA methylation; histone deacetylase inhibitor; histone modification; melanoma; miRNA

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; APICIDIN; AZACITIDINE; BELINOSTAT; BUTYRIC ACID; CISPLATIN; CYCLIN D2; DACARBAZINE; DACINOSTAT; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; DNA METHYLTRANSFERASE INHIBITOR; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ENTINOSTAT; EPIGALLOCATECHIN GALLATE; ETOPOSIDE; MG 98; MICRORNA; N PHTHALOYLTRYPTOPHAN; PROCAINAMIDE; ROMIDEPSIN; S 110; TACEDINALINE; TETRAPEPTIDE; TRAPOXIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; APOPTOSIS; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL INVASION; CELL PROLIFERATION; CELLULAR IMMUNITY; CHEMORADIOTHERAPY; CPG ISLAND; CUTANEOUS MELANOMA; CYTOTOXIC T LYMPHOCYTE; DEACETYLATION; DNA METHYLATION; DNA REPAIR; DOWN REGULATION; EPIGENETICS; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; HISTONE MODIFICATION; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; NUCLEOSOME; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SECONDARY STRUCTURE; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TUMOR INVASION; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT; UPREGULATION; WILD TYPE;

ANIMALS; CARCINOGENESIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL TRIALS AS TOPIC; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; HUMANS; IMMUNITY; IMMUNOTHERAPY; MELANOMA; MICRORNAS; MODELS, ANIMAL; MOLECULAR TARGETED THERAPY; SKIN NEOPLASMS;

EID: 84885227935     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.108     Document Type: Review

References (141)

1. Wu C, Morris JR. Genes, genetics, and epigenetics: A correspondence. Science 293(5532), 1103-1105 (2001).
2. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429(6990), 457-463 (2004).
3. Kanwal R, Gupta S. Epigenetic modifications in cancer. Clin. Genet. 81(4), 303-311 (2012).
4. Klose RJ, Bird AP. Genomic DNA methylation: The mark and its mediators. Trends Biochem. Sci. 31(2), 89-97 (2006).
5. Fratta E, Coral S, Covre A et al. The biology of cancer testis antigens: Putative function, regulation and therapeutic potential. Mol. Oncol. 5(2), 164-182 (2011).
6. Smith ZD, Meissner A. DNA methylation: Roles in mammalian development. Nat. Rev. Genet. 14(3), 204-220 (2013).
7. Hashimoto H, Vertino PM, Cheng X. Molecular coupling of DNA methylation and histone methylation. Epigenomics 2(5), 657-669 (2010).
8. Bogdanovic O, Veenstra GJ. DNA methylation and methyl-CpG binding proteins: Developmental requirements and function. Chromosoma 118(5), 549-565 (2009).
9. Cosgrove MS, Boeke JD, Wolberger C. Regulated nucleosome mobility and the histone code. Nat. Struct. Mol. Biol. 11(11), 1037-1043 (2004).
10. Iizuka M, Smith MM. Functional consequences of histone modifications. Curr. Opin. Genet. Dev. 13(2), 154-160 (2003).
11. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: A new frontier for drug discovery. Nat. Rev. Drug Discov. 11(5), 384-400 (2012).
12. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 403(6765), 41-45 (2000).
13. Fullgrabe J, Hajji N, Joseph B. Cracking the death code: Apoptosis-related histone modifications. Cell Death Differ. 17(8), 1238-1243 (2010).
14. Cheung P, Lau P. Epigenetic regulation by histone methylation and histone variants. Mol. Endocrinol. 19(3), 563-573 (2005).
15. Liang G, Lin JC, Wei V et al. Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proc. Natl Acad. Sci. USA 101(19), 7357-7362 (2004).
16. Kouzarides T. Chromatin modifications and their function. Cell 128(4), 693-705 (2007).
17. Pang Y, Young CY, Yuan H. MicroRNAs and prostate cancer. Acta Biochim. Biophys. Sin. (Shanghai) 42(6), 363-369 (2010).
18. Cowland JB, Hother C, Gronbaek K. MicroRNAs and cancer. APMIS 115(10), 1090-1106 (2007).
19. Zhang W, Dahlberg JE, Tam W. MicroRNAs in tumorigenesis: A primer. Am. J. Pathol. 171(3), 728-738 (2007).
20. Kim SK, Nam JW, Rhee JK, Lee WJ, Zhang BT. miTarget: MicroRNA target gene prediction using a support vector machine. BMC Bioinformatics 7, 411 (2006).
21. Zhao Q, Rank G, Tan YT et al. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat. Struct. Mol. Biol. 16(3), 304-311 (2009).
22. Tachibana M, Matsumura Y, Fukuda M, Kimura H, Shinkai Y. G9a/GLP complexes independently mediate H3K9 and DNA methylation to silence transcription. EMBO J. 27(20), 2681-2690 (2008).
23. Esteve PO, Chin HG, Benner J et al. Regulation of DNMT1 stability through SET7-mediated lysine methylation in mammalian cells. Proc. Natl Acad. Sci. USA 106(13), 5076-5081 (2009).
24. Wang J, Hevi S, Kurash JK et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat. Genet. 41(1), 125-129 (2009).
25. Chuang JC, Jones PA. Epigenetics and microRNAs. Pediatr. Res. 61(5 Pt 2), R24-R29 (2007).
26. Vrba L, Jensen TJ, Garbe JC et al. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS ONE 5(1), e8697 (2010).
27. Gronbaek K, Hother C, Jones PA. Epigenetic changes in cancer. APMIS 115(10), 1039-1059 (2007).
28. Kanai Y, Hirohashi S. Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. Carcinogenesis 28(12), 2434-2442 (2007).
29. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301(5895), 89-92 (1983).
30. Fan H, Zhao ZJ, Cheng J, Su XW, Wu QX, Shan YF. Overexpression of DNA methyltransferase 1 and its biological significance in primary hepatocellular carcinoma. World J. Gastroenterol. 15(16), 2020-2026 (2009).
31. Molognoni F, Cruz AT, Meliso FM et al. Epigenetic reprogramming as a key contributor to melanocyte malignant transformation. Epigenetics 6(4), 450-464 (2011).
32. Hou P, Liu D, Dong J, Xing M. The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle 11(2), 286-295 (2012).
33. Nguyen T, Kuo C, Nicholl MB et al. Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics 6(3), 388-394 (2011).
34. Deng T, Kuang Y, Wang L, Li J, Wang Z, Fei J. An essential role for DNA methyltransferase 3a in melanoma tumorigenesis. Biochem. Biophys. Res. Commun. 387(3), 611-616 (2009).
35. Sigalotti L, Fratta E, Coral S et al. Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications. J. Cell. Physiol. 212(2), 330-344 (2007).
36. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349(21), 2042-2054 (2003).
37. Jones PA. DNA methylation and cancer. Oncogene 21(35), 5358-5360 (2002).
38. Knudson AG. Hereditary cancer: Two hits revisited. J. Cancer Res. Clin. Oncol. 122(3), 135-140 (1996).
39. Armaghany T, Wilson JD, Chu Q, Mills G. Genetic alterations in colorectal cancer. Gastrointest. Cancer Res. 5(1), 19-27 (2012).
40. Sigalotti L, Covre A, Fratta E et al. Epigenetics of human cutaneous melanoma: Setting the stage for new therapeutic strategies. J. Transl. Med. 8, 56 (2010).
41. Schinke C, Mo Y, Yu Y et al. Aberrant DNA methylation in malignant melanoma. Melanoma Res. 20(4), 253-265 (2010).
42. Palmieri G, Capone M, Ascierto ML et al. Main roads to melanoma. J. Transl. Med. 7, 86 (2009).
43. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 365(9460), 687-701 (2005).
44. Freedberg De , Rigas SH, Russak J et al. Frequent p16-independent inactivation of p14ARF in human melanoma. J. Natl Cancer Inst. 100(11), 784-795 (2008).
45. Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 23(22), 4014-4022 (2004).
46. Marini A, Mirmohammadsadegh A, Nambiar S, Gustrau A, Ruzicka T, Hengge UR. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. J. Invest. Dermatol. 126(2), 422-431 (2006).
47. Rastetter M, Schagdarsurengin U, Lahtz C et al. Frequent intra-tumoural heterogeneity of promoter hypermethylation in malignant melanoma. Histol. Histopathol. 22(9), 1005-1015 (2007).
48. Spugnardi M, Tommasi S, Dammann R, Pfeifer GP, Hoon DS. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res. 63(7), 1639-1643 (2003).
49. Tanemura A, Terando AM, Sim MS et al. CpG island methylator phenotype predicts progression of malignant melanoma. Clin. Cancer Res. 15(5), 1801-1807 (2009).
50. Tellez CS, Shen L, Estecio MR, Jelinek J, Gershenwald JE, Issa JP. CpG island methylation profiling in human melanoma cell lines. Melanoma Res. 19(3), 146-155 (2009).
51. Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343(19), 1350-1354 (2000).
52. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA et al. Immunologic and clinical outcomes of a randomized Phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin. Cancer Res. 13(21), 6386-6395 (2007).
53. Brichard VG, Lejeune D. GSK?s antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development. Vaccine 25(Suppl. 2), B61-B71 (2007).
54. Odunsi K, Qian F, Matsuzaki J et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc. Natl Acad. Sci. USA 104(31), 12837-12842 (2007).
55. Sigalotti L, Fratta E, Coral S et al. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2́-deoxycytidine. Cancer Res. 64(24), 9167-9171 (2004).
56. Sigalotti L, Covre A, Zabierowski S et al. Cancer testis antigens in human melanoma stem cells: Expression, distribution, and methylation status. J. Cell Physiol. 215(2), 287-291 (2008).
57. Howell PM Jr, Liu S, Ren S, Behlen C, Fodstad O, Riker AI. Epigenetics in human melanoma. Cancer Control 16(3), 200-218 (2009).
58. Soengas MS, Capodieci P, Polsky D et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409(6817), 207-211 (2001).
59. Zhang XD, Gillespie SK, Borrow JM, Hersey P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol. Cancer Ther. 3(4), 425-435 (2004).
60. Tschiersch B, Hofmann A, Krauss V, Dorn R, Korge G, Reuter G. The protein encoded by the Drosophila position-effect variegation suppressor gene Su(var)3-9 combines domains of antagonistic regulators of homeotic gene complexes. EMBO J. 13(16), 3822-3831 (1994).
61. Jones RS, Gelbart WM. The Drosophila Polycomb-group gene enhancer of zeste contains a region with sequence similarity to trithorax. Mol. Cell. Biol. 13(10), 6357-6366 (1993).
62. Stassen MJ, Bailey D, Nelson S, Chinwalla V, Harte PJ. The Drosophila trithorax proteins contain a novel variant of the nuclear receptor type DNA binding domain and an ancient conserved motif found in other chromosomal proteins. Mech. Dev. 52(2-3), 209-223 (1995).
63. Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev. 18(19), 2315-2335 (2004).
64. Bachmann IM, Halvorsen OJ, Collett K et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 24(2), 268-273 (2006).
65. Cao Q, Yu J, Dhanasekaran SM et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27(58), 7274-7284 (2008).
66. Bracken AP, Kleine-Kohlbrecher D, Dietrich N et al. The polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 21(5), 525-530 (2007).
67. Jacobs JJ, Kieboom K, Marino S, De Pinho RA, van Lohuizen M. The oncogene and polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397(6715), 164-168 (1999).
68. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol. 2(10), 731-737 (2001).
69. Silva J, Garcia V, Garcia JM et al. Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Res. 9(4), R55 (2007).
70. Bachmann IM, Puntervoll HE, Otte AP, Akslen LA. Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. Mod. Pathol. 21(5), 583-590 (2008).
71. Mueller DW, Rehli M, Bosserhoff AK. miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J. Invest. Dermatol. 129(7), 1740-1751 (2009).
72. Bemis LT, Chen R, Amato CM et al. MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res. 68(5), 1362-1368 (2008).
73. Haflidadottir BS, Bergsteinsdottir K, Praetorius C, Steingrimsson E. miR-148 regulates Mitf in melanoma cells. PLoS ONE 5(7), e11574 (2010).
74. Segura MF, Hanniford D, Menendez S et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc. Natl Acad. Sci. USA 106(6), 1814-1819 (2009).
75. Chen X, Wang J, Shen H et al. Epigenetics, microRNAs, and carcinogenesis: Functional role of microRNA-137 in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 52(3), 1193-1199 (2011).
76. Liu S, Howell PM, Riker AI. Up-regulation of miR-182 expression after epigenetic modulation of human melanoma cells. Ann. Surg. Oncol. 20(5), 1745-1752 (2013).
77. Schultz J, Lorenz P, Gross G, Ibrahim S, Kunz M. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res. 18(5), 549-557 (2008).
78. Muller DW, Bosserhoff AK. Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma. Oncogene 27(52), 6698-6706 (2008).
79. Felicetti F, Errico MC, Segnalini P, Mattia G, Care A. MicroRNA-221 and-222 pathway controls melanoma progression. Expert Rev. Anticancer Ther. 8(11), 1759-1765 (2008).
80. Liu S, Kumar SM, Lu H et al. MicroRNA-9 up-regulates E-cadherin through inhibition of NF-kB1-Snail1 pathway in melanoma. J. Pathol. 226(1), 61-72 (2012).
81. Glud M, Manfe V, Biskup E et al. MicroRNA miR-125b induces senescence in human melanoma cells. Melanoma Res. 21(3), 253-256 (2011).
82. Lodygin D, Tarasov V, Epanchintsev A et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7(16), 2591-2600 (2008).
83. Migliore C, Petrelli A, Ghiso E et al. MicroRNAs impair MET-mediated invasive growth. Cancer Res. 68(24), 10128-10136 (2008).
84. Asangani IA, Harms PW, Dodson L et al. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget 3(9), 1011-1025 (2012).
85. Yan D, Zhou X, Chen X et al. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Invest. Ophthalmol. Vis. Sci. 50(4), 1559-1565 (2009).
86. Chen X, He D, Dong XD et al. MicroRNA-124a is epigenetically regulated and acts as a tumor suppressor by controlling multiple targets in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 54(3), 2248-2256 (2013).
87. Mazar J, De Blasio D, Govindarajan SS, Zhang S, Perera RJ. Epigenetic regulation of microRNA-375 and its role in melanoma development in humans. FEBS Lett. 585(15), 2467-2476 (2011).
88. Lyko F, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J. Natl Cancer Inst. 97(20), 1498-1506 (2005).
89. Yoo CB, Jeong S, Egger G et al. delivery of 5-aza-2́-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res. 67(13), 6400-6408 (2007).
90. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2́-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA De methylation. Proc. Natl Acad. Sci. USA 91(25), 11797-11801 (1994).
91. Gravina GL, Festuccia C, Marampon F et al. Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol. Cancer 9, 305 (2010).
92. Illustrates the biological significance and rationale for the clinical potential of DNA methyltransferase inhibitors in combination with other chemotherapeutics or ionizing radiation. The molecular basis and mechanisms of action for these combined treatments are also discussed.
93. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors 157. Nat. Rev. Drug Discov. 5(9), 769-784 (2006).
94. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: Overview and perspectives. Mol. Cancer Res. 5(10), 981-989 (2007).
95. Hoshino I, Matsubara H. Recent advances in histone deacetylase targeted cancer therapy. Surg. Today 40(9), 809-815 (2010).
96. Verdone L, Agricola E, Caserta M, Di Mauro E. Histone acetylation in gene regulation. Brief Funct. Genomic. Proteomic. 5(3), 209-221 (2006).
97. Garcia-Manero G. Demethylating agents in myeloid malignancies. Curr. Opin. Oncol. 20(6), 705-710 (2008).
98. Graham JS, Kaye SB, Brown R. The promises and pitfalls of epigenetic therapies in solid tumours. Eur. J. Cancer 45(7), 1129-1136 (2009).
99. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 27(32), 5459-5468 (2009).
100. Explores the biology of histone deacetylase enzymes, reviews the pharmacologic properties of histone deacetylase inhibitors, discusses results of selected clinical trials and also considers the potential of these inhibitors in combination therapy with targeted drugs, and with cytotoxic chemotherapy.
101. Coral S, Sigalotti L, Colizzi F et al. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: Immunotherapeutic implications. J. Cell. Physiol. 207(1), 58-66 (2006).
102. Weiser TS, Ohnmacht GA, Guo ZS et al. Induction of MAGE-3 expression in lung and esophageal cancer cells. Ann. Thorac. Surg. 71(1), 295-301 (2001).
103. Guo ZS, Hong JA, Irvine KR et al. Denovo induction of a cancer/testis antigen by 5-aza-2́-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res. 66(2), 1105-1113 (2006).
104. Schmelz K, Sattler N, Wagner M, Lubbert M, Dorken B, Tamm I. Induction of gene expression by 5-aza-2́-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and-independent mechanisms. Leukemia 19(1), 103-111 (2005).
105. Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: Implications for tumor immune escape. Cancer Immunol. Immunother. 53(10), 904-910 (2004).
106. Aptsiauri N, Cabrera T, Garcia-Lora A, Lopez-Nevot MA, Ruiz-Cabello F, Garrido F. MHC class I antigens and immune surveillance in transformed cells. In: International Review of Cytology: A Survey of Cell Biology. Kwang WJ (Ed.). Academic Press, MA, USA, 139-189 (2007).
107. Fonsatti E, Sigalotti L, Coral S, Colizzi F, Altomonte M, Maio M. Methylation-regulated expression of HLA class I antigens in melanoma. Int. J. Cancer 105(3), 430-431 (2003).
108. Romero JM, Jimenez P, Cabrera T et al. Coordinated downregulation of the antigen presentation machinery and HLA class I/b2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer 142. Int. J. Cancer 113(4), 605-610 (2005).
109. Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin. Cancer Biol. 12(1), 3-13 (2002).
110. Sigalotti L, Coral S, Fratta E et al. Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy. Semin. Oncol. 32(5), 473-478 (2005).
111. Coral S, Sigalotti L, Altomonte M et al. 5-aza-2́-deoxycytidine- induced expression of functional cancer testis antigens in human renal cell carcinoma: Immunotherapeutic implications. Clin. Cancer Res. 8(8), 2690-2695 (2002).
112. Chou SD, Khan AN, Magner WJ, Tomasi TB. Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells. Int. Immunol. 17(11), 1483-1494 (2005).
113. Coral S, Sigalotti L, Gasparollo A et al. Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2́-deoxycytidine (5-AZA-CdR). J. Immunother. 22(1), 16-24 (1999).
114. Fonsatti E, Nicolay HJ, Sigalotti L et al. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2́- deoxycytidine in cutaneous melanoma: Immunotherapeutic implications. Clin. Cancer Res. 13(11), 3333-3338 (2007).
115. Khan AN, Magner WJ, Tomasi TB. An epigenetic vaccine model active in the prevention and treatment of melanoma. J. Transl. Med 5, 64 (2007).
116. Magner WJ, Kazim AL, Stewart C et al. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J. Immunol. 165(12), 7017-7024 (2000).
117. Serrano A, Tanzarella S, Lionello I et al. Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2́-deoxycytidine treatment. Int. J. Cancer 94(2), 243-251 (2001).
118. Bae SI, Cheriyath V, Jacobs BS, Reu FJ, Borden EC. Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. Oncogene 27(4), 490-498 (2008).
119. Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, De batin KM. Sensitization for death receptor-or drug-induced apoptosis by re-expression of caspase-8 through De methylation or gene transfer. Oncogene 20(41), 5865-5877 (2001).
120. Reu FJ, Leaman DW, Maitra RR et al. Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons. Cancer Res. 66(5), 2785-2793 (2006).
121. Reu FJ, Bae SI, Cherkassky L et al. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA De methylation. J. Clin. Oncol. 24(23), 3771-3779 (2006).
122. Liu S, Ren S, Howell P, Fodstad O, Riker AI. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell Melanoma Res. 21(5), 545-558 (2008).
123. Khan AN, Magner WJ, Tomasi TB. An epigenetically altered tumor cell vaccine. Cancer Immunol. Immunother. 53(8), 748-754 (2004).
124. Khan AN, Gregorie CJ, Tomasi TB. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol. Immunother. 57(5), 647-654 (2008).
125. Murakami T, Sato A, Chun NA et al. Transcriptional modulation using HDACi De psipeptide promotes immune cell-mediated tumor De struction of murine B16 melanoma. J. Invest. Dermatol. 128(6), 1506-1516 (2008).
126. Gillespie S, Borrow J, Zhang XD, Hersey P. Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells. Apoptosis 11(12), 2251-2265 (2006).
127. Vo DD, Prins RM, Begley JL et al. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res. 69(22), 8693-8699 (2009).
128. Kato Y, Salumbides BC, Wang XF et al. Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Mol. Cancer Ther. 6(1), 70-81 (2007).
129. Hellebrekers DM, Jair KW, Vire E et al. Angiostatic activity of DNA methyltransferase inhibitors. Mol. Cancer Ther. 5(2), 467-475 (2006).
130. Alvino E, Castiglia D, Caporali S et al. A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: Role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system. Int. J. Oncol. 29(4), 785-797 (2006).
131. Christmann M, Pick M, Lage H, Schadendorf D, Kaina B. Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int. J. Cancer 92(1), 123-129 (2001).
132. Daud AI, Dawson J, De Conti RC et al. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: Translational and Phase I/II clinical trial. Clin. Cancer Res. 15(7), 2479-2487 (2009).
133. Valentini A, Gravina P, Federici G, Bernardini S. Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells. Cancer Biol. Ther. 6(2), 185-191 (2007).
134. Hauschild A, Trefzer U, Garbe C et al. Multicenter Phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]- benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res. 18(4), 274-278 (2008).
135. Munster PN, Marchion D, Thomas S et al. Phase I trial of vorinostat and doxorubicin in solid tumours: Histone deacetylase 2 expression as a predictive marker. Br. J. Cancer 101(7), 1044-1050 (2009).
136. Rocca A, Minucci S, Tosti G et al. A Phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br. J. Cancer 100(1), 28-36 (2009).
137. Munshi A, Kurland JF, Nishikawa T et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin. Cancer Res. 11(13), 4912-4922 (2005).
138. Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, Meyn RE. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of g-H2AX foci. Mol. Cancer Ther. 5(8), 1967-1974 (2006).
139. Sigalotti L, Covre A, Fratta E et al. Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients. J. Transl. Med. 10, 185 (2012).
140. Study that aimed to De fine the prognostic value of whole-genome DNA methylation profiles in stage III cutaneous melanoma patients.
141. Sigalotti L, Fratta E, Bidoli E et al. Methylation levels of the long interspersed nucleotide element-1 repetitive sequences predict survival of melanoma patients. J. Transl. Med. 9, 78 (2011).